The Therapeutic Goods Administration (TGA) has granted Comirnaty (BNT162b2 [mRNA]/tozinameran) COVID-19 Vaccine provisional approval for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, in individuals 5 years of ag

Medical Information
Australia
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Australian Healthcare Professionals. Would you like to proceed?

January 20, 2022

The Therapeutic Goods Administration (TGA) has granted Comirnaty® (tozinameran) COVID-19 Vaccine provisional approval for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, in individuals 5 years of age and older. The use of this vaccine should be in accordance with official recommendations.